Resources Repository
-
ArticlePublication 2022Comparing Health Gains, Costs & Cost-Effectiveness of Interventions in Australia & New Zealand
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New …
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New Zealand (NZ) from studies conducted with comparable methods, and reports results in the form of an online interactive league table. Studies from the Australia Cost-Effectiveness research and NZ Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programmes and studies were included which reported health-adjusted life years (HALYs) and net health system costs and/or incremental cost-effectiveness ratios, used a time horizon of…
Priority Setting/Ethics | Chronic Disease/Risk | Mental Health | Infectious Diseases | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | Asia & Pacific | Oceania -
ArticlePublication 2016Challenges of Prioritization
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and …
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and diagnostics; in addition, the evidence base drawn on for evaluating such interventions is relatively good, given the medical research industry surrounding their testing. However, with increasing success in controlling infectious diseases, many of the health challenges facing countries concern broad threats to health with multiple causes, such as obesity, where the relationship between policy action and health benefit is not…
Priority Setting/Ethics | Chronic Disease/Risk | Mental Health | Infectious Diseases | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Test Performance | Chronic Disease/Risk | Infectious Diseases | State-Transition | Microsimulation | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | Global | North America -
ArticlePublication 2017When Cost-Effective Interventions Are Unaffordable
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, …
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, little of the cost-effectiveness literature in global health addresses this issue. Budget impact analysis (BIA) describes an intervention's short-term costs and savings from the payer's perspective. This paper assesses the current use of budget impact analysis (BIA) and cost-effectiveness analysis (CEA) in health economic assessments conducted for low- and middle-income countries (LMICs). The authors recommend steps researchers and policymakers can…
Priority Setting/Ethics | Chronic Disease/Risk | Infectious Diseases | Costing Methods | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | Global -
ArticlePublication 2015Health Gains & Financial Risk Protection by Public Financing in Ethiopia: An ECEA
This article, published in the Lancet Global Health, aims to evaluate the health and financial …
This article, published in the Lancet Global Health, aims to evaluate the health and financial risk protection benefits of selected interventions that could be publicly financed by the government of Ethiopia. The authors used an extended cost-effectiveness analysis (ECEA) to assess the health gains (deaths averted) and financial risk protection afforded (cases of poverty averted) by a bundle of nine interventions that the Government of Ethiopia aims to make universally available. This approach incorporates financial…
Priority Setting/Ethics | Chronic Disease/Risk | Infectious Diseases | Mathematical Models | Cost-Effectiveness Analysis | Maternal/Reproductive Health | Child/Nutrition | Health Systems | Policy/Regulation | Health/Medicine | Sub-Saharan Africa -
ReportPublication 2015Modeling to Improve Policy Decisions in the Americas: Noncommunicable Diseases
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only …
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only to human health, but also to a country’s economic development and growth. The evidence on both of these counts is compelling. In 2012, cardiovascular disease, diabetes, cancers, chronic respiratory conditions including asthma, and other NCDs were the cause of 4.5 million deaths in the Americas. Of that total number, 1.5 million of them were premature, occurring among people aged 30-69…
Priority Setting/Ethics | Chronic Disease/Risk | Mental Health | Costing Methods | Mathematical Models | State-Transition | Microsimulation | Decision Analysis | Cost-Effectiveness Analysis | Health/Medicine | Latin America & Caribbean -
ArticlePublication 2008Cost-Effectiveness of Rapid Point-of-Care Prenatal Syphilis Screening in Sub-Saharan Africa
This paper investigates the cost-effectiveness of using rapid point-of-care tests for prenatal syphilis screening among …
This paper investigates the cost-effectiveness of using rapid point-of-care tests for prenatal syphilis screening among pregnant women in sub-Saharan Africa, a region with syphilis prevalence rates as high as 17%, and where traditional multi-test screening methods have been challenging to implement. Focusing on newly available rapid point-of-care screening tests, strategies differed by the initial test [rapid plasma reagin (RPR), immunochromographic strip (ICS)], need for confirmation with Treponema pallidum hemagglutination assay, and number of visits required.…
Test Performance | Infectious Diseases | Costing Methods | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Maternal/Reproductive Health | Clinical Care | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2023Performance of Rapid Antigen Tests to Detect Symptomatic and Asymptomatic SARS-CoV-2 Infection
The objective of this study was to evaluate the performance of rapid antigen tests (Ag-RDTs) …
The objective of this study was to evaluate the performance of rapid antigen tests (Ag-RDTs) for detection of SARS-CoV-2 among symptomatic and asymptomatic participants. The general findings were that the performance of Ag-RDTs was optimized when asymptomatic participants tested 3 times at 48-hour intervals and when symptomatic participants tested 2 times separated by 48 hours. Participants completed Ag-RDTs and reverse transcriptase polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 every 48 hours for 15 days. They…
Test Performance | Infectious Diseases | Clinical Care | Health/Medicine | Science/Technology | North America -
ArticlePublication 2020Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure
This study aimed to determine the false-negative rate of RT-PCR tests for SARS-CoV-2 infection based …
This study aimed to determine the false-negative rate of RT-PCR tests for SARS-CoV-2 infection based on the timeline of exposure and symptom onset. Drawing from data in seven studies involving 1,330 upper respiratory tract samples, a Bayesian model was used to estimate these rates. Findings showed that in the initial four days prior to typical symptom onset, the false-negative rate decreased from 100% on day 1 to 67% on day 4. By the day of…
Test Performance | Infectious Diseases | Clinical Care | Health/Medicine | Science/Technology | North America